Project Grant R21AI202296
Award Date 9/3/26
Completion Date 8/31/28
Dollars Obligated $228K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Athens, GA 30602, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded the University of Georgia Research Foundation $228,000 on July 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop enzymatic pipelines for the in vitro synthesis of parasitic glycosylphosphatidylinositol (GPI) anchors and GPI-anchored proteins. Parasitic infections affect more than one billion people globally. GPI anchors and GPI-anchored proteins are essential to parasite cell surfaces and...
- The National Institute of Allergy and Infectious Diseases awarded the University of Georgia Research Foundation, Inc. $675,790 on August 7, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct molecular analysis of transcription termination by RNA polymerase II in trypanosomatids. The research investigates epigenetic mechanisms of gene expression control in Trypanosoma brucei and Leishmania species, protozoan parasites that cause human African sleeping...
- The National Institute of Allergy and Infectious Diseases awarded the University of Georgia Research Foundation, Inc. $190,000 on September 2, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to identify Plasmodium liver-stage secreted effector proteins that enable parasite survival and immune evasion in hepatocytes. The project will map the secretome and interactome of Plasmodium falciparum and Plasmodium berghei in hepatocytes using proximity-dependent...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded $440,000 in Project Grant funding under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Texas Medical Branch at Galveston, effective July 3, 2025, through June 30, 2027. This award supports research to determine the function and mechanism of long non-coding RNA CHAST in Trypanosoma cruzi infection and dissemination, which causes Chagas disease. The...
- The National Institute of Allergy and Infectious Diseases awarded $436,750 to the University of Georgia Research Foundation on July 3, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct cellular and molecular profiling of artemisinin-induced persister phenotypes in Plasmodium falciparum. The research addresses the emergence of artemisinin resistance in malaria parasites and focuses on understanding how the parasites enter a dormant ring stage when exposed...
- The National Institute of Allergy and Infectious Diseases awarded $400,932 to the University of Georgia Research Foundation, Inc. on February 2, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support research into immunity induced by cryptococcal morphological strains in CD4+ T cell-deficient hosts. The research addresses cryptococcal meningoencephalitis, which accounts for more than 15 percent of total AIDS-related deaths globally, with mortality rates...
- The National Institute of Allergy and Infectious Diseases awarded the University of Georgia Research Foundation $1,023,862 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to produce and distribute filarial research reagents through the Filariasis Research Reagent Resource Center (FR3). The award funds three specific aims over a five-year period ending August 31, 2031. Under Aim 1, the recipient will ensure continued provision of high-quality...
- The National Institute of Allergy and Infectious Diseases awarded $157,500 to the University of California, Los Angeles on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support basic research on the structure and ligand binding of receptor adenylate cyclase from Trypanosoma brucei, a flagellated eukaryotic parasite responsible for African trypanosomiasis. The research examines cAMP signaling pathways in T. brucei, focusing on receptor-type adenylate...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Fundacion Instituto De Investigaciones Biotecnologicas a Project Grant of $133,746 under the Allergy and Infectious Diseases Research program (CFDA 93.855) effective September 9, 2025, with completion scheduled for August 31, 2030. This research initiative conducts high-throughput analysis of antibody response dynamics against defined epitopes of Trypanosoma cruzi to identify and prioritize...
- Federal Project Grant Award Summary The University of Cincinnati's Sponsored Research Services Division received a $444,688 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective July 1, 2025 through June 30, 2027. This award funds biomedical research focused on characterizing cyclic adenosine monophosphate (cAMP) signaling microdomains in Trypanosoma cruzi, the protozoan parasite...